Skip to content

Sometimes, an innovation makes immediate use of just one valuable insight. More often, an innovation emerges in a way that may feel sudden and violent, but in reality is the result of years of work across different fields. This quarter, the exciting innova­tions we chose are largely the latter type. Across the board, they combine progress from fields as diverse as robotics and materials science to invent ingenious new forms that build on previous advancements. What unites them is their potential to impact our world and economy far beyond their initial use cases.

Advanced new robot “dog” uses reinforcement learning to do parkour

A team at Carnegie Mellon University recently created a robotic dog that jumps up blocks twice its height, deals with tricky terrain and can rove freely.1 Reinforcement learning, a technique that uses artificial intelligence (AI) to mimic how humans learn, enables this new robot dog to respond dynamically to its environment.

Why it matters: Researchers have changed focus to how a robot’s “mind” can learn to perform new actions with its body. As a result, robots are increasingly agile and responsive to their environments. This shift in approach may allow robots to learn how to perform basic daily tasks on our behalf.

New AI model can predict how proteins change in interactions with molecules

The first version of AlphaFold, a protein structure predictor, came out in 2020. In 2024, AlphaFold was updated in a major breakthrough—it can now predict the structures of proteins during interactions with other molecules with startling accuracy.2

Why it matters: The developers of AlphaFold hope to increase the power of the technology. The goal is to predict the structure of the >100,000 proteins in our bodies both by themselves and in interactions. If achieved, this would be a foundational advancement for drug discovery, moving it from the lab onto the computer.

Exhibit 1: Illustration of Protein Structure

Using artificial intelligence to predict protein structures is a foundational advancement for drug discovery

For illustrative purposes only.

Yeast-like bacteria found to digest carbon and produce ethanol

One of the answers to climate change may have been found in rabbit feces—the bacterium clostridum autoethanogenum.3 Like yeast, which eats sugar to make ethanol, this bacterium eats gaseous carbon and produces ethanol. One company is capturing waste carbon emissions from steel plants and placing them in a bioreactor with the bacteria.

Why it matters: The climate benefit of this innovation is twofold. First, these bacteria could produce a 30% drop in carbon emissions for steel plants, an industry responsible for 11% of global emissions. Second, the resulting ethanol can be used to make aviation fuel with 85% less carbon emissions.4

Researchers invent a shapeshifting robot

A new miniature robot that can change from liquid to solid takes its inspiration from the flexible sea cucumber.5 By embedding magnetic particles within the metal gallium, researchers built a robot with similar flexibility. It can jump up to 20 times its body length, climb walls, and even escape from a mock prison.

Why it matters: Although it is early, this new robot shows promise in biomedical applications. For instance, it could be used to remove a coin from a human stomach. Beyond medicine, it may be able to help assemble and repair hard-to-reach circuits or even act as a universal screw.

Advances in geothermal energy may help curb carbon emissions

New ideas to solve old problems can be found in the most unlikely of places. In this case, geothermal energy, one of the most promising forms of renewable energy, has emerged as a new application for hydraulic fracking.6 Solid stone at unprecedented depth is cracked, and water is injected. This produces steam, which drives turbines to produce electricity for the grid.

Why it matters: Today, less than 1% of energy is geothermal. But, geothermal energy, like fossil fuels, doesn’t vary with weather conditions or time of day, a major limiting factor for other renewable energy technologies. This means it could power the grid when other renewables are less available.



IMPORTANT LEGAL INFORMATION

This material is intended to be of general interest only and should not be construed as individual investment advice or a recommendation or solicitation to buy, sell or hold any security or to adopt any investment strategy. It does not constitute legal or tax advice. This material may not be reproduced, distributed or published without prior written permission from Franklin Templeton.

The views expressed are those of the investment manager and the comments, opinions and analyses are rendered as at publication date and may change without notice. The underlying assumptions and these views are subject to change based on market and other conditions and may differ from other portfolio managers or of the firm as a whole. The information provided in this material is not intended as a complete analysis of every material fact regarding any country, region or market. There is no assurance that any prediction, projection or forecast on the economy, stock market, bond market or the economic trends of the markets will be realized. The value of investments and the income from them can go down as well as up and you may not get back the full amount that you invested. Past performance is not necessarily indicative nor a guarantee of future performance. All investments involve risks, including possible loss of principal.

Any research and analysis contained in this material has been procured by Franklin Templeton for its own purposes and may be acted upon in that connection and, as such, is provided to you incidentally. Data from third party sources may have been used in the preparation of this material and Franklin Templeton ("FT") has not independently verified, validated or audited such data.  Although information has been obtained from sources that Franklin Templeton believes to be reliable, no guarantee can be given as to its accuracy and such information may be incomplete or condensed and may be subject to change at any time without notice. The mention of any individual securities should neither constitute nor be construed as a recommendation to purchase, hold or sell any securities, and the information provided regarding such individual securities (if any) is not a sufficient basis upon which to make an investment decision. FT accepts no liability whatsoever for any loss arising from use of this information and reliance upon the comments, opinions and analyses in the material is at the sole discretion of the user.

Products, services and information may not be available in all jurisdictions and are offered outside the U.S. by other FT affiliates and/or their distributors as local laws and regulation permits. Please consult your own financial professional or Franklin Templeton institutional contact for further information on availability of products and services in your jurisdiction.

Issued in the U.S. by Franklin Distributors, LLC, One Franklin Parkway, San Mateo, California 94403-1906, (800) DIAL BEN/342-5236, franklintempleton.com - Franklin Distributors, LLC, member FINRA/SIPC, is the principal distributor of Franklin Templeton U.S. registered products, which are not FDIC insured; may lose value; and are not bank guaranteed and are available only in jurisdictions where an offer or solicitation of such products is permitted under applicable laws and regulation.

Canada: Issued by Franklin Templeton Investments Corp., 200 King Street West, Suite 1500 Toronto, ON, M5H3T4, Fax: (416) 364-1163, (800) 387-0830, www.franklintempleton.ca

Offshore Americas: In the U.S., this publication is made available only to financial intermediaries by Franklin Distributors, LLC, member FINRA/SIPC, 100 Fountain Parkway, St. Petersburg, Florida 33716. Tel: (800) 239-3894 (USA Toll-Free), (877) 389-0076 (Canada Toll-Free), and Fax: (727) 299-8736. Investments are not FDIC insured; may lose value; and are not bank guaranteed. Distribution outside the U.S. may be made by Franklin Templeton International Services, S.à r.l. (FTIS) or other sub-distributors, intermediaries, dealers or professional investors that have been engaged by FTIS to distribute shares of Franklin Templeton funds in certain jurisdictions. This is not an offer to sell or a solicitation of an offer to purchase securities in any jurisdiction where it would be illegal to do so.

Issued in Europe by: Franklin Templeton International Services S.à r.l. – Supervised by the Commission de Surveillance du Secteur Financier - 8A, rue Albert Borschette, L-1246 Luxembourg. Tel: +352-46 66 67-1 Fax: +352-46 66 76. Poland: Issued by Templeton Asset Management (Poland) TFI S.A.; Rondo ONZ 1; 00-124 Warsaw. South Africa: Issued by Franklin Templeton Investments SA (PTY) Ltd, which is an authorized Financial Services Provider. Tel: +27 (21) 831 7400 Fax: +27 (21) 831 7422. Switzerland: Issued by Franklin Templeton Switzerland Ltd, Talstrasse 41, CH-8001 Zurich. United Arab Emirates: Issued by Franklin Templeton Investments (ME) Limited, authorized and regulated by the Dubai Financial Services Authority. Dubai office: Franklin Templeton, The Gate, East Wing, Level 2, Dubai International Financial Centre, P.O. Box 506613, Dubai, U.A.E. Tel: +9714-4284100 Fax: +9714-4284140. UK: Issued by Franklin Templeton Investment Management Limited (FTIML), registered office: Cannon Place, 78 Cannon Street, London EC4N 6HL. Tel: +44 (0)20 7073 8500. Authorized and regulated in the United Kingdom by the Financial Conduct Authority. 

Australia: Issued by Franklin Templeton Australia Limited (ABN 76 004 835 849) (Australian Financial Services License Holder No. 240827), Level 47, 120 Collins Street, Mellbourne, Victoria 3000. Hong Kong: Issued by Franklin Templeton Investments (Asia) Limited, 17/F, Chater House, 8 Connaught Road Central, Hong Kong. Japan: Issued by Franklin Templeton Japan Co., Ltd., Shin-Marunouchi Building, 1-5-1 Marunouchi Chiyoda-ku, Tokyo 100-6536, registered in Japan as a Financial Instruments Business Operator [Registered No. The Director of Kanto Local Finance Bureau (Financial Instruments Business Operator), No. 417]. Korea: Issued by Franklin Templeton Investment Trust Management Co., Ltd., 3rd fl., CCMM Building, 12 Youido-Dong, Youngdungpo-Gu, Seoul, Korea 150-968. Malaysia: Issued by Franklin Templeton Asset Management (Malaysia) Sdn. Bhd. & Franklin Templeton GSC Asset Management Sdn. Bhd. This document has not been reviewed by Securities Commission Malaysia. Singapore: Issued by Templeton Asset Management Ltd. Registration No. (UEN) 199205211E, 7 Temasek Boulevard, #38-03 Suntec Tower One, 038987, Singapore.

Please visit www.franklinresources.com to be directed to your local Franklin Templeton website.